ViroVet NV, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock, is proud to announce that it has successfully confirmed the efficacy of its porcine reproductive and respiratory syndrome (PRRS) vaccine based on the PLLAV or plasmid-launched live attenuated virus technology.
ViroVet are pioneers in developing novel and innovative vaccines based on a unique and proprietary technology platform originating from the Rega Institute for Medical Research of the Leuven University (KU Leuven). With this technology platform, vaccines can be designed and produced faster and more cost-effectively. PLLAV vaccines are tailor-made and thermostable thereby removing any cold-chain requirement.
ViroVet completed a dose-ranging study in weaned piglets with its PLLAV-based PRRS vaccine. In this study, vaccine doses in the microgram range of naked DNA successfully induced a specific antibody response to the PRRS virus. In addition, interferon-gamma responses were also shown which clearly highlights the ability of the PLLAV vaccine to activate cell-mediated immunity. A single vaccine shot was found to be effective in attaining these responses.
“After our successful BVD studies confirming the potential of our antiviral drug, we are happy to reach strong proof-of-concept data on the vaccine side of our company as well.”Erwin Blomsma, CEO of ViroVet
Nesya Goris, CDO of ViroVet adds that “Injecting naked DNA and thereby triggering both arms of the immune system is quite exciting as cell-mediated immunity as well as antibody immunity play a critical role in protecting pigs from PRRS virus infection.”
George Gunn, Chairman of the Board: “To take a novel and disruptive technology from research stage in academic labs to a successful proof-of-concept in swine in less than 4 years shows the potential of this PLLAV technology. In the next 12 to 15 months I expect that the company will be able to make a firm statement about its technology as well as its future.”
Bron: Blosma E. (2020, 22 October). ‘First vaccine based on ViroVet PLLAV technology enters development’, ViroVet NV. Geraadpleegd van https://bit.ly/3dVKhxH
ViroVet is a pioneering company dedicated to the development of disruptive and innovative technologies for the control of viral diseases in livestock, with antiviral drugs (video) for respiratory disease complexes and innovative vaccines (video) for viral infections in poultry and swine leading the pipeline. Temporarily, ViroVet also supports COVID19 vaccine development at the Rega Institute of KU Leuven.